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Abstract
Although United States smoking rates have been on the decline over the past few decades, 
cigarette smoking still poses a critical health and economic threat. Very few treatment options for 
smoking exist, and many of them do not lead to long-term abstinence. Preclinical models are 
necessary for understanding the effects of nicotine and developing treatments. Current self-
administration models of nicotine intake may require surgical procedures and often result in low 
levels of intake. Further, they do not lend themselves to investigating treatments. The current study 
sought to develop a limited-access model of nicotine intake using the Drinking-in-the-Dark 
paradigm, which results in high levels of binge-like ethanol consumption that can be 
pharmacologically manipulated. The present study found that mice will consume nicotine under a 
range of parameters. Intakes under the preferred condition of 0.14 mg/ml nicotine in 0.2% 
saccharin reached over 6 mg/kg in two hours and were reduced by an injection of R(+)-baclofen. 
Mecamylamine did not significantly affect nicotine consumption. As nicotine and ethanol are 
often co-abused, nicotine intake was also tested in the presence of ethanol. When presented in the 
same bottle, mice altered nicotine intake under various concentrations to maintain consistent levels 
of ethanol intake. When nicotine and ethanol were presented in separate bottles, mice greatly 
reduced their nicotine intake while maintaining ethanol intake. In conclusion, these studies 
characterize a novel model of limited-access nicotine intake that can be pharmacologically 
manipulated.
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1 Introduction1
Although cigarette smoking is on the decline, the Centers for Disease Control (CDC) 
estimates that as of 2013, 17.8% of the US population was classified as current smokers. 
Further, cigarette smoking accounts for 1 out of 5 deaths, making it the leading cause of 
preventable disease. The economic cost of first- and secondhand smoke is vast. Almost $170 
billion is spent yearly on medical care, whereas another $156 billion is lost in productivity 
due to smoking related illness (CDC). Approximately 68.8% of current smokers want to 
quit, yet quitting often takes multiple attempts and less than 10% of those who try to quit 
smoking successfully quit for at least 6 months (Messer et al., 2008).
Preclinical animal models, specifically those involving self-administration, can serve as a 
valuable tool to research the mechanisms of nicotine addiction as well as potential 
pharmacological treatments. Intravenous self-administration of nicotine mimics the rapid 
onset of nicotine inhalation in smokers (Lynch et al., 2010) and allows for quantification of 
how reinforcing the drug is. However, intravenous methods of self-administration require 
specific equipment, surgical catheter implantation, surgery recovery time, monitoring of 
catheter patency and pH of administered solutions, and often extensive operant training and 
food restriction to achieve escalation of responses and significant nicotine administration 
(Caille et al., 2012; Lynch et al., 2010).
Although non-operant oral self-administration studies do not offer the ability to quantify 
how reinforcing drugs of abuse are, they do allow for observation of self-administration and 
pharmacological manipulation of oral consumption. Few oral nicotine consumption studies 
have been conducted in mice. Of these, all but one has utilized 24 hr, 2-bottle choice 
paradigms. Adriani et al., (2002) observed intakes around 0.8–1.2 mg/kg nicotine using a 
limited 2hr 2-bottle choice paradigm in male and female CD-1 mice. Although intakes were 
low, they produced pharmacologically relevant levels of cotinine, the main metabolite of 
nicotine. However, mice were also water deprived during the 22 hours of the day when 
nicotine was not present. C57Bl/6J (B6) mice have routinely been shown to consume more 
nicotine than other strains in 24 hr free- choice access paradigms. Relatively high levels of 
intake are consistent across nicotine concentration (Glatt et al., 2009; Klein et al., 2004; 
Locklear et al., 2012) and are not changed when a sweetener is introduced to the nicotine 
and non-nicotine solution or related to intake of sweetened solutions (Meliska et al., 1995; 
Robinson et al., 1996). These results may suggest that B6 mice are insensitive to the bitter 
taste of quinine relative to other inbred strains, particularly at higher concentrations. 
However, using a brief-access paradigm that reliably quantifies aversion to quinine, Glatt et 
al. (2009) demonstrated that B6 mice display similar oral aversion as other strains to 
increasing concentrations of nicotine.
The purpose of the current studies was to develop a limited-access model of rapid nicotine 
intake in B6 mice that was more suitable for testing potential pharmacotherapies than 
previous oral nicotine administration paradigms. We chose to model nicotine intake using 
the Drinking-in-the-Dark (DID) method developed for 20% ethanol. In the DID paradigm, 
1C57Bl/6J (B6), Centers for Disease Control (CDC), Drinking-in-the-Dark (DID), nicotinic acetylcholine receptors (nAChRs)
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B6 mice consume high binge-like levels of ethanol at rates that are much more rapid than 
during 24 hr free-choice access paradigms (Matson & Grahame, 2011; Rhodes et al., 2005). 
We sought to characterize whether B6 mice would consume nicotine in a similar limited 
access, binge-like fashion, and under what specifications their intake was optimized by 
substituting ethanol for multiple concentrations of nicotine alone or nicotine with saccharin. 
In humans, smoking one cigarette over 5 minutes leads to absorption of approximately 0.3–2 
mgs nicotine and smokers maintain cotinine levels of approximately 250–300 ng/ml 
(Hukkanen et al., 2005). It is important to note that, unlike ethanol, there is no clinical 
definition of what constitutes a nicotine “binge.” Therefore, we refer to our model as a 
limited access, restricted period of rapid consumption without indicating clinical relevance.
Further, we sought to pharmacologically manipulate binge-like nicotine intake, as traditional 
ethanol DID offers a model that lends itself to prompt testing of pharmacological targets for 
alcohol and substance use disorders, unlike 24 hr drinking models. To do so, we used the 
nAChR antagonist mecamylamine and the GABAB agonist R(+)-baclofen. Mecamylamine is 
often used to precipitate nicotine withdrawal whereas baclofen attenuates the negative 
effects of nicotine withdrawal (Varani et al., 2014). Both of these drugs reduce ethanol 
intake in the DID paradigm and baclofen has been shown to reduce smoking behavior in a 
clinical trial (Franklin et al., 2009; Hendrickson et al., 2009; Kasten et al., 2015; Leggio et 
al., 2015). Finally, we sought to characterize whether B6 mice would co-consume nicotine 
and alcohol, as is often the case in human addiction (National Institute on Alcohol Abuse 
and Alcoholism, 2007), and whether co-consumption could be pharmacologically 
manipulated.
2 Method
2.1 Animals
All animals were male B6 mice maintained on a 12:12 light cycle in facilities accredited by 
the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). 
In all studies mice were at least 60 days old at the beginning of testing. Animals had access 
to food and water at all times, apart from during nicotine and/or ethanol presentation when 
water was not available. All procedures were approved by the IUPUI School of Science 
Institutional Animal Care and Use Committee and conformed to the Guide for the Care and 
Use of Laboratory Animals (The National Academic Press, 2003).
2.2 Drugs
(−)Nicotine hemisulfate salt dissolved in H2O (~40% w/v freebase) was purchased from 
Sigma Aldrich (St. Louis, MO). Nicotine was dissolved in quantities of 87.5, 175, and 262.5 
μl per 500 ml of tap water to respective salt-form doses of 0.07, 0.14, and 0.21 mg/ml. 
Respective freebase nicotine doses for these concentrations were 0.028, 0.056, and 0.084 
mg/ml. Saccharin was obtained from Sigma Aldrich (St. Louis, MO) and was dissolved in a 
0.025% or 0.2% w/v solution using tap water. Ethanol (195 proof) was obtained from 
Pharmco, Inc. (Brookefield, CT), and solutions (10% v/v and 20% v/v) were made using tap 
water. R(+)-baclofen hydrochloride and mecamylamine hydrochloride were obtained from 
Sigma Aldrich (St. Louis, MO) and dissolved in 0.9% saline to concentrations of 0, 3, 6.5, 
Kasten et al. Page 3
Pharmacol Biochem Behav. Author manuscript; available in PMC 2017 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
and 10 mg for R(+)-baclofen studies and 0, 0.75, 1.5, and 3mg for mecamylamine studies. 
Baclofen and mecamylamine solutions were delivered via intraperitoneal injections in a 
volume of 0.1ml per 10g of body weight. Experimental procedures including animal and 
drug usage are outlined in Table 1. All drug injections took place on Day 5 immediately 
prior to fluid access.
2.3 Experiment 1: Limited-Access Nicotine Intake
Nicotine intake was characterized in 18 male B6 mice taken from our breeding colony 
maintained at IUPUI. These mice were first generation offspring of breeders purchased from 
Jackson Laboratories. For all studies, fluid was presented daily in 10 ml graduated tubes for 
two hours, three hours into the dark cycle. Fluid level was read to the nearest 0.05 ml at the 
beginning and end of the two hour access period. Empty “leak” cages were maintained for 
each fluid to determine fluid leakage over the 2 hr access periods. Intake was calculated as 
fluid displacement for each individual mouse minus the fluid leak.
In Experiment 1, animals received 0.21 mg/ml nicotine in water alone, in water containing 
0.025% saccharin, or in water containing 0.2% saccharin for five days of access. Following 
two weeks of water washout, the same animals were given five days of access to 0.14 mg/ml 
nicotine in 0, 0.025, or 0.2% saccharin. Groups were counterbalanced based on saccharin 
concentration during 0.21 mg/ml nicotine access. The 0.21 and 0.14 mg/ml doses fall within 
the high range of nicotine concentrations used in 24 hr free-choice access studies. Further, 
nicotine-naïve B6 mice should have slight and no aversion to the 0.21 and 0.14 mg/ml 
concentrations, respectively (Glatt et al., 2008), allowing us to better understand how 
nicotine concentrations and saccharin edulcoration alters oral nicotine consumption.
During access to 0.14 mg/ml nicotine, mice were placed in an Opto M3 13″×9″ Mouse 
Cages locomotor activity system (Columbus Instruments, Columbus, OH). The animal’s 
cage is placed directly into the monitor and locomotor scores are determined based on 
sensor beam breaks. Each cage monitor was started immediately following introduction of 
the reinforcer. Locomotor activity scores were collected in 5 minute bins during the two 
hours of reinforcer access and two hours post-reinforcer access.
2.4 Experiment 2: Pharmacological Manipulation of Limited-Access Nicotine Intake
A total of 64 male B6 mice were purchased from Jackson Laboratories. For pharmacological 
manipulation of nicotine intake, 0.14 mg/ml nicotine in 0.2% saccharin was used because it 
generated high levels of nicotine intake with low variability. Animals received 5 days of 
nicotine access. Thirty-two animals were administered 0, 3, 6.5, or 10 mg/kg of R(+)-
baclofen. The remaining 32 animals were administered 0, 0.75, 1.5, or 3 mg/kg of 
mecamylamine. Doses were based on previous ethanol DID findings (Hendrickson et al., 
2009; Kasten et al., 2015). On day 5, drug was administered immediately prior to bottles on 
and a fluid intake was monitored at bottles-on, hour 1, and hour 2 to observe time-specific 
effects on intake. Dose groups were counterbalanced based on Day 4 nicotine intake and 
variance in intake across the 4 day acquisition phase.
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2.5 Experiment 3: Nicotine + Ethanol Limited-Access Intake
Because smoking and alcohol use disorders are highly comorbid, we also investigated co-
consumption of nicotine and ethanol intake. Thirty-eight male mice were used to examine 
co-consumption of nicotine and ethanol. These mice had previously been used in a pilot 
study that was completed at least 3 weeks prior to the current study and had a 5 or 10 day 
history of 0.14 mg/ml nicotine in 0.2% saccharin or 0.2% saccharin alone. Three 
concentrations of nicotine (0.07, 0.14, or 0.21 mg/ml) were presented in two concentrations 
of saccharin (0.025% or 0.2%). These six concentrations were all combined in an ethanol 
solution so that the nicotine, ethanol, and saccharin were administered in one bottle. Not all 
the groups were tested simultaneously. To observe whether mice would consume a nicotine 
+ ethanol combination, the 0.14 mg/ml nicotine + 0.2% saccharin group was piloted prior to 
the other groups, and given 4 days of reinforcer access. On day 1 the nicotine solution was 
mixed with 20% ethanol according to standard DID. However, the 20% concentration 
limited the amount of fluid animals consumed, thereby reducing the amount of nicotine 
consumed. Therefore, on days 2–4, the ethanol solution was switched to 10% to increase 
fluid intake. Although the solution was changed, the dependent variables of g/kg of ethanol 
and mg/kg of nicotine consumed were calculated in the same manner as all other data points. 
Therefore, the data is included without any adjustments in the statistics and accompanying 
figure. The 0.07 mg/ml + 0.025%, 0.07 mg/ml + 0.2%, 0.14 mg/ml + 0.025%, 0.21 mg/ml 
+ 0.21 mg/ml + 0.025%, and 0.21 mg/ml + 0.2% groups were all run concurrently. Animals 
were given access to the nicotine + saccharin solutions in one bottle containing 10% ethanol. 
Fluid levels were recorded at the beginning and end of the 2 hour access period, and amount 
of ethanol and nicotine intake was quantified.
2.6 Experiment 4: Pharmacological Manipulation of Nicotine + Ethanol Limited-Access 
Intake
A total of 54 male B6 mice purchased from Jackson Laboratories were used to quantify the 
effects of baclofen and mecamylamine on concurrent nicotine and ethanol access. These 
mice were not naïve. As part of a previous unrelated study, they had been exposed to 48 
hours of a 2-bottle free choice paradigm with access to two water bottles (n = 36), or one 
water bottle and one bottle containing up to 0.35 mM quinine (n = 18). The prior quinine 
exposure took place three weeks prior to the current study and was accounted for in drug and 
dose assignments.
All mice received fluid access to two bottles for 5 days. One bottle contained 0.14 mg/ml 
nicotine in 0.2% saccharin, and the other contained 20% ethanol in 0.2% saccharin. Two 
bottles were used in place of combined solution because intake of the combined solution 
appeared to be driven by ethanol intake, and we wanted to discern the independent effects of 
drug on each solution. Bottle position was randomized and changed daily. Immediately prior 
to bottles-on on day 5, animals received an injection of saline, R(+)-baclofen (3, 6.5, or 10 
mg/kg), or mecamylamine (0.75, 1.5, or 3 mg/kg). To conserve animal usage, the same 
control group was used for each drug. Fluid readings were taken at bottles on, hour 1, and 
hour 2 to observe time-course specific effects on intake. Dosage groups were 
counterbalanced based on Day 4 ratio of ethanol to nicotine intake, variance in ratio of 
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ethanol to nicotine intake over the acquisition phase, day 4 ethanol intake, and day 4 nicotine 
intake.
2.7 Statistics
Statistics were run using SPSS version 23 or GraphPad Prism 5. Statistical significance was 
set at p = 0.05. Significance levels were adjusted for all post-hoc tests. All data is reported as 
mean ± standard error of the mean (SEM). Nicotine intake and nicotine + ethanol intake was 
analyzed using a repeated measures Saccharin Concentration*Day or Nicotine 
Concentration*Saccharin Concentration*Day ANOVA. Cumulative locomotor activity 
scores during 2 hrs of 0.14 mg/ml nicotine access and for the 2 hrs post-access were 
analyzed using a Saccharin Concentration*Day ANOVA to assess locomotor activity scores 
in the same manner as nicotine drinking. Secondary ANOVAs and Tukey’s post-hoc tests 
were used as follow-up tests. Pearsons correlations were also run for Days 1–5 to assess the 
relationship between nicotine drinking and locomotor activity across all groups.
For all pharmacological tests, nicotine and ethanol acquisition was analyzed using a repeated 
measures ANOVA for day 1–4 intake. Day 5 intake was analyzed using a repeated measures 
Dose*Hour ANOVA. One-Way ANOVAs with dose at the between-subjects factor were also 
used to analyze total Day 5 drinking, as well as hour 1 and hour 2 consumption to assess the 
a priori hypotheses that drug effects would vary over time. Repeated measures Dose*Hour 
and one-way hourly ANOVAS were also used to assess drug dose effects on ethanol intake 
ratio, calculated as [ml/kg of ethanol consumed/(ml/kg of ethanol + ml/kg of nicotine 
consumed)], in the two-bottle tasks. Dunnett’s tests were used as post-hoc tests for dose 
main effects and hourly one-way ANOVAs, with the saline group set as the control.
3 Results
3.1 Limited-Access Nicotine Intake
A repeated measures Day*Saccharin concentration ANOVA was run to analyze intake of 
0.21 mg/ml nicotine. Greenhouse-Geisser statistics are reported due to significant 
differences in variability between groups (Mauchly’s test for sphericity; p < .001). There 
was no significant main effect of day on intake, nor was there a significant interaction (p’s 
> .05). There was a significant main effect of saccharin concentration, with the 0.2% 
concentration increasing nicotine intake compared to the 0% and 0.025% concentrations (p’s 
< .05) (Fig. 1A).
To analyze intake of 0.14 mg/ml nicotine in differing saccharin concentrations a repeated 
measures Day*Concentration ANOVA was used. There was a significant main effect of Day 
with a linear and quadratic pattern (p’s < .05). There was also significant main effect of 
Saccharin Concentration, F(2,18) = 36.39, p < .001. Mice consumed significantly more 
nicotine in the 0.2% saccharin solution than in the 0.025% or 0% solutions (p’s < .001). 
There was also a significant Day*Concentration interaction, F(8,72) = 2.98, p < .01. One-
way ANOVAs for each day of intake indicated that nicotine intake was significantly different 
between saccharin concentrations on all days, with the 0.2% saccharin group consuming 
more than the 0.025% and 0% saccharin groups on Days 1–5 (Fig. 1B).
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A Day*Concentration ANOVA was used to analyze locomotor activity during the two hours 
of 0.14 mg/ml nicotine access. One animal was removed because it was repeatedly found to 
be hanging on the cage top outside of the range of the beams, making its activity count 
inaccurate. There was no significant interaction of Day*Saccharin Concentration. However, 
there was a main effect of Day with a quadratic and cubic trend (p’s < .05). There was also a 
significant main effect of saccharin concentration, F(2,17) = 6.23, p < .01. Tukey’s post-hoc 
tests revealed that the 0.2% saccharin group was significantly more active than the 0.025% 
saccharin group (p < .01) and trended towards being more active than the nicotine alone 
group (p = .057) (Fig. 1C). Correlations assessing the direct relationship between daily 
nicotine intake and locomotor score revealed no significant relationship on Days 1 or 2 (p’s 
> .05). Nicotine intake was significantly correlated with locomotor activity on Days 3–5, 
r(20) = 0.566, 0.628, and 0.484, respectively (p’s < .05).
Locomotor activity for the 2 hrs post-reinforcement (0.14 mg/ml nicotine) access was also 
analyzed using a Day*Saccharin Concentration ANOVA. There was a main effect of day 
with a significant linear trend (p’s < .01). The main effect of saccharin concentration also 
reached significance, F(2,17) = 3.73, p = .046. Across days, the 0.2% saccharin group was 
significantly more active than the 0.25% saccharin group for the 2 hrs post-reinforcement 
access (p = .042). There was also a significant Day*Concentration interaction, F(8,68) = 
2.22, p < .05. Follow-up one-way ANOVAs for each day revealed significant concentration 
effects on Days 2, 4, and 5 (p’s < .05). The 0.2% saccharin group was significantly more 
active than the 0.025% saccharin group on Days 2 and 5 (p’s < .05) and trended towards 
being significantly more active on Day 4 (p = .051). The 0.2% saccharin group was also 
significantly more active than the nicotine alone group on Day 5 (p < .05) (Fig. 1D). 
Correlations between daily nicotine intake and post-reinforcement activity revealed a 
significant relationship only on Day 5 of access, r(20) = 0.582, p < .01.
3.2 Pharmacological Manipulation of Limited-Access Nicotine Intake: Baclofen
A repeated measures ANOVA on day 1–4 intake revealed no effect of day on nicotine 
acquisition; F(3,93) = 1.48, p > .05 (Fig. 2A). A repeated measures Hour*Dose ANOVA on 
day 5 revealed no significant effect of hour on intake (p > .05). There was a trend towards an 
Hour*Dose interaction, but it did not reach significance (p = .075). However, on day 5 there 
was a significant effect of Dose on total 2 hour intake; F(3,28) = 9.9, p < .001. Dunnett’s 
post-hoc tests revealed that all doses of baclofen significantly reduced total nicotine intake 
compared to the saline group (p’s < .01) (Fig. 2B). ANOVAs on hourly day 5 intake revealed 
a significant effect of dose at each hour (p’s < .01). At hour 1, all doses of baclofen 
significantly reduced nicotine intake (p’s < .01). However, at hour 2, although the 6.5 and 10 
mg/kg baclofen doses significantly reduced nicotine intake (p’s < .001), the 3 mg/kg dose 
only trended towards reducing intake (p = .059) (Fig. 2C).
3.3 Pharmacological Manipulation of Limited-Access Nicotine Intake: Mecamylamine
A repeated measures ANOVA on day 1–4 intake revealed a significant effect of day on 
nicotine acquisition; F(3,93) = 2.91, p < .05 (Fig. 2D). Follow-up paired-samples t-tests 
adjusted for multiple comparisons revealed that intake on Day 4 was significantly higher 
than Day 2 intake (p < .05), and trended towards being higher than Day 1 intake (p = .06). A 
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repeated measures Hour*Dose ANOVA revealed no significant effect of dose on total day 5 
intake; F(3,28) = 1.36, p > .05 (Fig. 2E). There was a significant effect of hour; F(1,28) = 
23.93, p < .001), with intake being significantly higher in hour 1. There was also an 
interaction between Hour*Dose; F(3,28) = 3.30, p < .05). One-way ANOVAs at each hour 
revealed no significant effect of Dose at either hour (p’s > .05) (Fig. 2F).
3.4 Nicotine + Ethanol Limited-Access Intake: Same Bottle
A repeated measures Nicotine Concentration*Saccharin Concentration*Day ANOVA 
revealed a main effect of day on ethanol intake; F(3,96) = 2.75, p < .05. There was a 
significant linear trend in the data, with ethanol intake increasing over days (p < .05). There 
was also a main effect of saccharin dose; F(1,32) = 12.19, p = .001. Animals consumed more 
ethanol when given access to the solution with 0.2% saccharin compared to animals given 
access to solution with 0.025% saccharin (p < .05). There was no main effect of nicotine 
concentration on ethanol intake, or any significant interactions between the variables (p’s > .
05) (Fig. 3A, 3C).
A repeated measures Nicotine Concentration*Saccharin Concentration*Day ANOVA 
revealed a main effect of day on nicotine consumption, which was linear in pattern; F(3,96) 
= 15.52, p < .001. As with ethanol intake, there was a significant effect of saccharin 
concentration; F(1,32) = 4.63, p < .05. Animals that received access to the 0.2% saccharin 
concentration consumed more nicotine than those that received access to the 0.025% 
concentration (p < .05). There was also a main effect of nicotine; F(2,32) = 77.15, p < .001. 
Animals receiving the 0.14 mg/ml concentration drank significantly more nicotine than 
those receiving the 0.07 mg/ml concentration, and the animals receiving 0.21 mg/ml drank 
significantly more than both other groups (p’s < .001). There was a significant interaction of 
Nicotine Concentration*Day; F(6,96) = 4.850, p < .001. One-way ANOVAs for each day 
revealed a significant effect of Nicotine Concentration each day, which followed the same 
pattern as the nicotine main effect (p’s < .05). Although the omnibus Nicotine 
Concentration*Saccharin Concentration*Day ANOVA trended towards significance (p = .
057), there were no other significant interactions (Fig. 3B, 3D).
3.5 Pharmacological Manipulation of Nicotine + Ethanol Limited-Access Intake: Separate 
Bottles, Baclofen
A repeated measures ANOVA revealed a significant effect of day with a linear and cubic 
pattern on ethanol acquisition; F(3,90) = 8.04, p < .001 (Fig. 4A). An Hour*Dose repeated 
measures ANOVA on day 5 revealed no interaction of Hour*Dose. However, there was an 
effect of hour, with animals consuming more ethanol in the first hour; F(1,27) = 19.287, p 
< .001. There was also a significant main effect of dose; F(3,27) = 5.03, p < .01. Dunnett’s 
post-hoc test revealed that the 6.5 and 10 mg/kg dose of R(+)-baclofen significantly reduced 
total ethanol intake compared to the control group (p’s < .05) (Fig. 4B). One-way ANOVAs 
at each hour revealed only a significant effect of dose at hour one, which followed the same 
pattern as effect of dose on total intake (p’s < .05) (Fig. 4C).
A repeated measures ANOVA revealed no effect of day on nicotine acquisition (p > .05) 
(Fig. 4D). An Hour*Dose repeated measures ANOVA on day 5 revealed no significant main 
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effects or interactions of the variables on nicotine intake (p’s > .05). One-way ANOVAs also 
revealed no significant effect of R(+)-baclofen at either hour on nicotine intake (p’s > .05) 
(Figs. 4E, F).
Finally, an Hour*Dose repeated measures ANOVA revealed no significant main effects or 
interactions on ethanol intake ratio following drug administration (p’s > .05). There were 
also no significant effects of dose at either hour (p’s > .05). Total mean ethanol intake ratio ± 
SEM was 0.86 ± 0.08 for 0 mg/kg, 0.84 ± 0.04 for 3 mg/kg, 0.74 ± 0.11 for 6.5 mg/kg, and 
0.91 ± 0.04 for 10 mg/kg.
3.6 Pharmacological Manipulation of Nicotine + Ethanol Limited-Access: Separate Bottles, 
Mecamylamine
A repeated measures ANOVA revealed a significant effect of day with a linear trend on 
acquisition of ethanol intake; F(3,90) = 13.44, p < .05 (Fig. 5A). An Hour*Dose repeated 
measures ANOVA on day 5 revealed only a main effect of hour on ethanol intake, with more 
ethanol being consumed in the first hour; F(1,27) = 16.86, p < .001. One-way ANOVAS to 
assess effect of dose on hourly intake revealed no significant effect of dose at either hour on 
ethanol intake (p’s > .05) (Figs. 5B,C).
A repeated measures ANOVA revealed no effect of day on nicotine acquisition (p > .05) 
(Fig. 5D). An Hour*Dose repeated measures ANOVA on day 5 revealed no significant main 
effects or interaction of mecamylamine dose*hour on nicotine intake (p’s > .05). One-way 
ANOVAs also revealed no significant effect of mecamylamine at either hour on nicotine 
intake (p’s > .05) (Figs. 5E,F).
Finally, an Hour*Dose repeated measures ANOVA revealed no significant main effects or 
interactions on ethanol intake ratio following drug administration (p’s > .05). There were 
also no significant effects of dose at either hour (p’s > .05). Total mean ethanol intake ratio ± 
SEM was 0.86 ± 0.08 for 0 mg/kg, 0.82 ± 0.07 for 0.75 mg/kg, 0.65 ± 0.10 for 1.5 mg/kg, 
and 0.63 ± 0.14 for 3 mg/kg.
4 Discussion
The current studies were completed to identify what concentrations of nicotine B6 mice will 
consume in a limited-access paradigm, whether nicotine and ethanol would be co-consumed, 
and whether R(+)-baclofen and mecamylamine are able to reduce nicotine alone and 
nicotine + ethanol consumption in a manner similar to that of ethanol consumption. The 
current studies demonstrated that male B6 mice will binge-consume nicotine under multiple 
conditions, with intakes reaching averages at and above 6 mg/ml of nicotine salt 
concentrations (approximately 2.4 mg/ml freebase) when nicotine is added to a 0.2% 
saccharin solution (Fig. 1). This intake is significantly reduced by R(+)-baclofen, but not 
significantly altered by mecamylamine (Fig. 2). The mice also co-consumed nicotine and 
ethanol, but greatly reduced their nicotine intake when ethanol was concurrently presented 
in a separate bottle (Figs. 3–5). During concurrent nicotine and ethanol access in separate 
bottles, R(+)-baclofen significantly reduced ethanol intake, but no longer significantly 
altered nicotine intake (Fig. 4). Mecamylamine again did not alter nicotine intake, but also 
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failed to reduce concurrent ethanol intake (Fig. 5), although it has been previously shown to 
reduce ethanol intake at these doses using a similar procedure (Hendrickson et al., 2009).
Although cotinine levels were not assessed, the mice in the current study drank nicotine at 
levels far surpassing that which have previously been shown to produce pharmacologically 
relevant cotinine levels. Adriani et al. (2002) demonstrated that an intake of 1 mg/kg over 1 
hr resulted in cotinine levels seen following a 0.2–0.3 mg/kg i.p. nicotine injection, and that 
intakes of 3 mg/kg over 1 hr resulted in locomotor effects. In the current study, we saw 
significantly increased locomotor activity during and after access to 0.14 mg/ml nicotine in 
0.2% saccharin. Under these conditions, mice were consuming over 8 mg/kg of nicotine by 
Day 3 of access (Fig. 1). Although locomotor activity did not increase over days during 
access, it did become significantly correlated with nicotine intake by Day 3 across all 
groups, indicating a change in response to nicotine intake at an individual level. Activity 
post-reinforcement did change in a linear pattern across days, also possibly indicating an 
adaptation to repeated nicotine intake (Fig. 1C, D).
It is unclear if the current levels and duration of drinking would result in upregulation of 
nAChRs. Previous studies have observed upregulation of nAChRs following injection of 
0.45–4 mg/kg nicotine twice daily, micropump infusion of 9.6 mg/kg nicotine over 24 hours, 
and 24 hr oral consumption of nicotine (Wonnacott, 1990; Sparks & Pauly, 1999; Nashmi et 
al., 2007; Ribeiro-Carvalho et al., 2008). These studies used 10 to 30 days of nicotine 
exposure, which is much longer than the exposure employed in the current studies. However, 
with extended access it is likely that upregulation would be seen given the high levels of 
intake in the current studies. Similar intakes have also been shown to result in somatic 
withdrawal symptoms during 28 days of access, but not 14, indicating that the duration of 
access in the current studies may not produce somatic withdrawal (Grabus et al., 2004 
Locklear et al., 2012). Questions of cotinine levels, somatic withdrawal, and nAChR 
upregulation can be answered with time-course studies. Cotinine has a half-life of 
approximately 38 minutes in B6 mice (Siu & Tyndale, 2007), therefore samples should be 
taken to assess cotinine levels at half-hour time points in different subgroups of mice. 
Although the metabolic capacity of the mouse is likely to differ from that of humans, daily 
smokers maintain cotinine levels of around 250–300 ng/ml, which can be reached in mice 
(Grabus et al., 2004; Hukkanen et al., 2005).
One concern in the present study is the need to edulcorate nicotine solutions with saccharin 
so that they become palatable. Although mice drink low, but potentially relevant (Adriani et 
al., 2002; Klein et al., 2004) levels of nicotine without saccharin present, saccharin 
significantly increases the intake of 0.14 mg/ml nicotine. This is contrary to Robinson et al. 
(1996), who found that addition of a sweetener did not significantly increase nicotine intake 
across various concentrations in B6 mice. However, the previous study used a 2-bottle 
choice paradigm and saccharin was added to both the nicotine and non-nicotine solution 
without comparing how addition of saccharin only to the nicotine solution would affect 
intake. Saccharin on its own can be pharmacologically manipulated, which confounds the 
interpretation of drug effects on nicotine intake. Testing each drug on saccharin intake can 
help to interpret drug effects on reinforcers that need to be supplemented with saccharin. In 
the current study the 3 mg/kg dose of R(+)-baclofen significantly reduced nicotine 
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consumption, although we have previously shown that this dose is not sufficient to reduce 
consumption of 0.2% saccharin alone in the DID paradigm. These results were also unlikely 
to be due to locomotor suppression, as the high dose of 10 mg/kg R(+)-baclofen does not 
reduce home cage locomotor activity during access to 0.2% saccharin or 20% ethanol, even 
though it reduces concurrent reinforcer intake (Kasten et al., 2015). The 6.5 mg/kg dose also 
significantly reduced nicotine intake (Fig. 2). Unpublished data from our lab has shown that 
6.5 mg/kg of R(+)-baclofen significantly reduces 20% ethanol, but not 0.2% saccharin 
intake in the DID paradigm, suggesting a reinforcer-specific effect at this dose. 
Unexpectedly, addition of saccharin to the 20% ethanol solution did not cause an increase in 
ethanol intake over consumption levels that have been previously demonstrated in our lab 
(Fritz et al., 2014; Kasten et al., 2015; Moore et al., 2007).
Using a lower concentration of nicotine may alleviate the need for adding saccharin to the 
fluid. Aversion begins to occur at a concentration of around .05 mg/ml nicotine in naïve 
mice (Glatt et al., 2009). However, at this low concentration mice may consume significantly 
less nicotine, as it would require approximately 3 times the fluid intake as the 0.14 mg/ml 
concentration. Using concentrations of nicotine higher than 0.21 mg/ml without the addition 
of saccharin may bifurcate the population into groups that are sensitive and insensitive to the 
aversive taste of nicotine and lead to great variance in intakes. For example, female rats that 
consume more quinine also consume more nicotine, potentially indicating decreased taste 
sensitivity (Nesil et al., 2015). Therefore, edulcorating nicotine with saccharin may be of 
less concern than using nicotine alone.
Concurrent access to nicotine and ethanol in the same or separate bottles led to different 
nicotine intakes. When nicotine and ethanol were given in the same bottle, mice consumed 
the same amount of ethanol regardless of nicotine concentration, leading to significantly 
different nicotine intakes ranging from around 2 mg/kg to 6 mg/kg (Fig. 3). When nicotine 
and ethanol were simultaneously presented in different bottles mice consumed the same 
amount of ethanol as when nicotine was given in the same bottle, but drastically reduce their 
nicotine intake (Figs. 4 & 5). From the same bottle, mice consuming 20% ethanol in 0.14 
mg/ml nicotine + 0.2% saccharin averaged an ethanol intake of 2.97 g/kg (Fig. 2C). From 
separate bottles mice consumed 3.67 mg/kg and 3.62 mg/kg of ethanol across the acquisition 
days for the baclofen and mecamylamine studies, respectively. When presented in the same 
bottle, the ethanol + 0.14 mg/ml nicotine + 0.2% saccharin mice consumed an average 4.55 
mg/kg of nicotine. When given in separate bottles in the baclofen and mecamylamine 
studies, mice consumed an average of 1.21 mg/kg and 1.19 mg/kg nicotine across 
acquisition days, respectively. Similar patterns in operant lever responses of female alcohol 
preferring P rats for nicotine and ethanol solutions were observed by Hauser et al. (2012). 
Under various conditions the rats responded for nicotine + saccharin or nicotine + ethanol + 
saccharin. However, responses for ethanol alone were significantly higher when the animals 
were given a choice of 15% ethanol alone, 15% ethanol + 0.07 mg/ml nicotine, or 15% 
ethanol + 0.14 mg/ml nicotine. These results strongly indicate a preference for ethanol alone 
over access to a separate nicotine solution. B6 mice may simply prefer 20% ethanol in 0.2% 
saccharin over the nicotine + saccharin solution. Making ethanol less salient by increasing 
the concentration or removing the saccharin may begin to equalize nicotine and ethanol 
intake.
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Such low levels of nicotine intake are very unlikely to be pharmacologically relevant and 
make it difficult to assess any effects of drugs, such as baclofen, which reduce nicotine 
intake on their own. Along with ethanol preference, capacity to consume more fluid may 
have interfered with the animals’ ability to increase their nicotine intake. During 
consumption of 0.14 mg/ml nicotine alone, 10% ethanol + 0.14 mg/ml nicotine in the same 
bottle, and 20% ethanol and 0.14 mg/ml nicotine in different bottles animals consumed 
approximately 35 ml/kg of total fluid over the acquisition period. Increasing the nicotine 
concentration to 0.21 mg/ml in the separate bottle paradigm may allow for increased 
nicotine consumption with decreased fluid intake. Mice in the mecamylamine groups 
appeared to increase their nicotine fluid intake without decreasing their ethanol fluid intake. 
However, there was no significant difference in ethanol intake ratio (section 3.6). It should 
also be noted that on the test day the control group reduced its nicotine intake by more than 
1 mg/ml whereas the group that received 1.5 mg/kg mecamylamine kept steady nicotine 
intake from days 4–5, indicating an injection effect on the test day. There was a similar 
effect on ethanol intake from days 4–5 (see Fig. 5).
Another important variable is the time course of nicotine intake versus the time course of 
ethanol intake. The data herein suggest relatively consistent levels of nicotine intakes within 
the first and second hours of consumption, whereas ethanol intake tends to be higher in the 
first hour (Figs. 4 & 5). Using volumetric drinking devices, Linsenbardt and Boehm (2014) 
characterized a very distinct pattern of DID drinking in B6 mice that changes from steady 
intake across the first session to a front-loading pattern with a late increase in drinking on 
day 14 of access. Assessing discrete patterns of nicotine intake alone versus nicotine + 
ethanol intake using volumetric drinking devices may further reveal important time-course 
characteristics of nicotine intake across repeated access sessions and how concurrent ethanol 
access changes patterns of nicotine and ethanol intake.
As demonstrated herein, the limited-access model offers ability to pharmacologically 
manipulate nicotine intake without the concerns of the 24 hr paradigms, such as interference 
of or need for water access, intake being spread across the day, or determining injection 
time-point. Current therapeutics, such as varenicline, can be tested to further verify the 
model for testing of potential pharmaceutical treatments for nicotine intake. Although it 
visually appears that mecamylamine increases nicotine-alone intake in the first hour of 
access, there were no significant effects of mecamylamine at any time point in any study 
(Figs. 2 & 5). This includes our inability to replicate a significant reduction in ethanol intake 
by the 3 mg/kg mecamylamine dose demonstrated to be effective by Hendrickson et al. 
(2009). However, because mice were concurrently consuming nicotine this may be due to an 
interaction between nicotine and ethanol. Notably, our results reveal that R(+)-baclofen 
reduces nicotine intake at all doses when nicotine is given alone (Fig. 2). Although it could 
be argued that there is a floor effect preventing baclofen from reducing nicotine intake when 
ethanol was concurrently presented in a different bottle, it is important to note that nicotine 
intake only visually trends towards decreasing in the 10 mg/kg dose (Fig. 4). Once again, 
this may suggest interactive effects between nicotine and ethanol. Also of note is that the 6.5 
mg/kg dose of R(+)-baclofen, which has not previously been tested in ethanol DID, 
significantly reduced ethanol intake.
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As previously discussed, rates of smoking are significantly higher in alcoholics, which is 
possibly due to similar underlying mechanisms. A history of alcohol use disorders 
significantly increases number of cigarettes smoked and aspects of cigarette smoking, such 
as increased time smoking per cigarette and number of puffs (Keenan et al., 1990) . It has 
been proposed that treating comorbid smoking is essential to recovery from alcohol use 
disorders (Prochaska, 2010). A recent review by Roche et al. (2016) outlines many different 
behavioral factors that contribute to smoking in heavy drinkers. These include the tendency 
for heavy-drinking smokers to show more stimulation than sedation to the effects of ethanol, 
use of one substance leading to craving for the other substance, increased motivation or loss 
of resistance to use both substances while using one substance, and using one substance to 
enhance the positive reinforcing effects or reduce the negative reinforcing effects of the other 
substance. Co-abuse may lead to less sedation, enhanced calming and euphoric effects, and 
reduced cognitive impairing effects of ethanol leading to development of cross-tolerance and 
comorbid alcohol and tobacco use disorders (Roche et al., 2016). Translational pre-clinical 
to human ethanol + nicotine co-consumption conclusions are difficult to draw from the 
current research due to limitations such as use of one in-bred strain, a consistent 5 day 
exposure period, and differences seen when ethanol and nicotine were combined in one 
bottle versus given concurrently in two separate bottles. However, the factors described by 
Roche et al. (2016) as being important for heavy-drinking smokers can be modeled using 
parameters of the current work. Stimulation response to ethanol can be accounted for as a 
potential moderator of concurrent nicotine intake across time using the two-bottle concurrent 
access model. The changes in topography of ethanol and nicotine drinking may also be 
observed over time in the two-bottle current access model. Following varying lengths of 
two-bottle concurrent exposure, nicotine alone, or ethanol alone, multiple behavioral models 
may be used to examine nicotine and ethanol cross-tolerance and whether it changes as 
function of duration of exposure. Operant-responding and extinction paradigms can be used 
to assess motivation and craving for nicotine + ethanol using the nicotine doses described 
within.
Nicotine and ethanol also share similar molecular and neurological pathways. Preclinical 
models have demonstrated that nicotine and ethanol, like other drugs of abuse, activate the 
dopaminergic pathway from the ventral tegmental area to the nucleus accumbens and other 
regions as well as increase dopamine release in the nucleus accumbens. In the case of 
nicotine and ethanol these effects are mediated in part by nAChRs, which are widely 
expressed in the ventral tegmental area on dopaminergic and GABAergic neurons 
(Hendrickson et al., 2013). Pharmaceuticals used to treat smoking or alcoholism have later 
been found to be effective in treating both disorders in heavy smoking and drinking clinical 
populations, such as varenicline and baclofen (Fucito et al., 2011; Franklin et al., 2009; 
Leggio et al., 2015; McKee et al., 2009; Mitchell et al., 2012). Agonism of GABAergic 
receptors in this region may generally work to inhibit intake of drugs of abuse, whereas 
agonism of nAChRs by varenicline may work in a similar way to mediate intake via 
GABAergic and dopaminergic agonism (Hendrickson et al., 2013). In the case of 
antagonism with mecamylamine, which is used to induce nicotine withdrawal, animals may 
continue to consume nicotine in an attempt to overcome the aversive effects of nAChR 
antagonism. Conversely, baclofen blocks mecamylamine-induced withdrawal symptoms 
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(Varani et al., 2011; 2014). Differences in mechanism of action and effects on withdrawal 
symptomology may explain the opposing effects of mecamylamine and R(+)-baclofen on 
oral nicotine consumption.
In conclusion, these studies demonstrate that male B6 mice will binge-consume nicotine 
under multiple parameters, R(+)-baclofen is able to reduce binge nicotine consumption, and 
that mice will co-consume ethanol and nicotine in a binge paradigm, although nicotine 
intake is greatly reduced when reinforcers are given in separate bottles. The current binge-
like model presents a simple and quick pre-clinical paradigm to assess potential treatments 
for smoking cessation, as well as smoking and ethanol disorders. Avenues for future 
research include reducing nicotine and saccharin concentrations, analyzing the time course 
of nicotine intake during concurrent ethanol access, and assessing the parameters of the 
models in females, which have previously been shown to have higher levels of 24-hour free-
choice intake (Glatt et al., 2009; Klein et al., 2004; Locklear et al., 2012; Meliska et al., 
1995). Most importantly, a time-course of cotinine levels should be assessed during and after 
nicotine exposure. Although this model shows high levels of intake, it is important to keep in 
mind that physiological changes, such as rates of metabolism or alterations in receptor 
expression, have not yet been quantified. Further, it is unclear whether this model leads to 
behavioral changes, such as nicotine withdrawal symptoms or changes in anxiety and 
cognition that are commonly associated with cigarette smoking.
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Highlights
• C57Bl/6J mice will consume high levels of nicotine in a limited-access 
model.
• Nicotine intake can be attenuated by R(+)-baclofen, but not 
mecamylamine.
• Mice will alter nicotine intake to maintain consistent ethanol intake.
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Figure 1. 
Figure 1 shows the amount of nicotine consumed at 0.21 mg/ml (A) or 0.14 mg/ml (B) in no 
saccharin, 0.025% saccharin, or 0.2% saccharin. The higher saccharin concentration 
increased intake of both nicotine concentrations. The higher saccharin concentration also 
altered locomotor activity during the 2 hours of access (C) and for the two hours after access 
(D) to 0.14 mg/ml nicotine. Asterisk (*) indicates p < .05, double asterisk (**) indicates p < .
01, triple asterisk (***) indicates p < .001, and hashtag (#) indicates significant one-way 
ANOVA for day.
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Figure 2. 
Figure 2 indicates the effect of baclofen and mecamylamine on 0.14 mg/ml nicotine + 0.2% 
saccharin intake in one-bottle DID. Panel A shows acquisition of intake for the baclofen 
experiment. All doses of baclofen significantly reduced total nicotine intake (B) with hourly 
effects (C). Panel D shows acquisition of intake for the mecamylamine experiment. 
Mecamylamine administration did not significantly affect total (E) or hourly (F) nicotine 
intake at any dose. Asterisk (*) indicates p < .05, double asterisk (**) indicates p < .01, 
triple asterisk (***) indicates p < .001, hashtag (#) indicates p = .059, n’s = 8 for panels B 
and C, n’s = 11 for panels E and F.
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Figure 3. 
Figure 3 indicates daily ethanol (A) and nicotine (B) intake of combined nicotine + ethanol. 
There was a main effect of saccharin concentration on average ethanol (C) and nicotine (D) 
consumption. Nicotine intake was also significantly different across nicotine concentrations. 
Asterisk (*) indicates p < .05, triple asterisk (***) indicates p < .001, n’s = 6–7.
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Figure 4. 
Figure 4 shows the effects of baclofen on consumption of 20% ethanol and 0.14 mg/ml 
nicotine in separate bottles during concurrent access. Both bottles contained 0.2% saccharin. 
Ethanol acquisition is shown in Panel A. Baclofen reduced total (B) and hourly (C) 20% 
ethanol intake. Nicotine acquisition is shown in Panel D. Baclofen did not affect total (C) 
and hourly (D) 0.14 mg/ml nicotine intake. Double asterisk (**) indicates p < .01, triple 
asterisk (***) indicates p < .001, n’s = 7–8.
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Figure 5. 
Figure 5 shows the effect of mecamylamine on consumption of 20% ethanol and 0.14 mg/ml 
nicotine in separate bottles during concurrent access. Both bottles contained 0.2% saccharin. 
Ethanol acquisition is shown in Panel A. Mecamylamine did not affect total (B) or hourly 
(C) 20% ethanol intake. Nicotine acquisition is shown in Panel D. Mecamylamine did not 
affect total (E) or hourly (F) 0.14 mg/ml nicotine intake, n’s = 7–8.
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Table 1
Study Length Fluid Access Drug administered Group size
Experiment 1 5 Days 0.21 or 0.14 mg/ml nicotine in 0, 0.025, 
or 0.2% saccharin
n/a n’s = 6
Experiment 2 5 Days 0.14 mg/ml nicotine in 0.2% saccharin R(+)-baclofen (0, 3, 6.5, 10 mg/kg) 
or mecamylamine (0, 0.75, 1.5, 3 
mg/kg)
R(+)-baclofen n’s = 8 
Mecamylamine n’s = 
11
Experiment 3 4–5 Days 0.07, 0.14, or 0.21 mg/ml nicotine in 
0.025 or 0.2% saccharin. All bottles 
contained 10% ethanol.
n/a n’s = 6–7
Experiment 4 5 Days One bottle of 0.14 mg/ml nicotine in 
0.2% saccharin and one bottle of 20% 
ethanol in 0.2% saccharin
R(+)-baclofen (0, 3, 6.5, 10 mg/kg) 
or mecamylamine (0, 0.75, 1.5, 3 
mg/kg)
All n’s = 7–8
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